Geriatrics
Latest News
Preventing breaks and falls in older adults
“The idea that a “bone attack” is like a heart attack gets the message across.”
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
News
FDA approves first drug to treat Alzheimer’s agitation
“Agitation is one of the most common and challenging aspects of care among patients with dementia due to Alzheimer’s disease.”
Conference Coverage
High cholesterol in seniors: Use statins for primary prevention?
Statins may be reasonable to prescribe, even given the risks that have been linked to statins, such as that for muscle pain.
From the Journals
Risk assessment first urged for fragility fracture screening
A new guideline is aimed at primary care practitioners for their community-dwelling patients aged 40 and older.
Pearl of the Month
Medications that scare me
Many medications can cause cardiac symptoms and other serious side effects in elderly patients.
From the Journals
Hearing aids are a ‘powerful’ tool for reducing dementia risk
“The evidence is building that hearing loss may be the most impactful modifiable risk factor for dementia in mid-life.”
Conference Coverage
Mammography after breast cancer: No benefit for older patients?
“Ongoing surveillance mammography in these patients may lead to overdiagnosis and overtreatment of cancers that potentially would not harm...
Conference Coverage
Active older women show heightened AFib risk
Low baseline cardiovascular risk factors showed no apparent association with later atrial fibrillation
News from the FDA/CDC
FDA approves first RSV vaccine for older adults
Older adults with underlying health conditions, such as lung or heart disease, are at high risk for severe disease.
Conference Coverage
Donanemab bests aducanumab in head-to-head Alzheimer’s trial
Nearly 40% of patients treated with donanemab had amyloid clearance at 6 months compared with less than 2% of those who received aducanumab.